KLK3 and Familial prostate cancer: In 2012, the US Food and Drug Administration approved prostate cancer associated 3 (PSA3) as a novel marker of prostate cancer to use when the combined results of repeated biopsy, PSA concentration, and digital rectal examination are controversial.